We have previously published that allo-HSCT recipient mice with a selective deficiency for IFN-I receptor signaling in CD11c+ dendritic cells (CD11creposIFNaR1floxed mice) still develop reduced GVHD after treatment with 3pRNA prior to allo-HSCT5. The gene discussed is ITGAX; the disease is graft versus host disease.